Latest Pulse
- Aug 10, 2026Biotech IPO Window Closes Its Strongest Week Since SpringBlossomHill and Latigo Biotherapeutics both closed upsized IPOs by August 10, capping a four-deal stretch that also included Braveheart Bio and Attovia Therapeutics pricing above or near the top of their ranges.→
- Aug 8, 2026Biotech IPOs Are Pricing Above Range AgainBlossomHill and Braveheart Bio both upsized and priced above their original ranges this week, the clearest two-deal signal yet that the biotech IPO window -- closed to all but the strongest names in 2024-2025 -- is reopening.→
- Aug 7, 2026BlossomHill Prices Upsized $150M IPO, Debuts on NasdaqBlossomHill Therapeutics priced an upsized IPO at $16 a share for $150M and began trading on Nasdaq under BLSM, more than 50% above the $100M target Pulse flagged when the company first filed.→
- Aug 3, 2026BlossomHill Files for $100M Nasdaq IPO in Cancer DrugsBlossomHill Therapeutics filed for a $100M Nasdaq IPO under ticker BLSM, adding an oncology-focused biotech with $257M in prior funding to a summer pipeline of clinical-stage listings led by J.P. Morgan, Leerink and Guggenheim.→
- Jul 16, 2026Seven Companies File S-1s in a Single WeekSeven companies spanning biotech, fintech, AI and battery materials filed IPO registration paperwork with the SEC within days of each other, a broad-based cluster that extends the sustained widening of 2026's listing pipeline.→
Coverage Timeline
newest firstAll Coverage
IPO$150M IPO
BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq
BlossomHill Therapeutics priced an upsized IPO at $16 a share for $150M and began trading on Nasdaq under BLSM, more than 50% above the $100M target Pulse flagged when the company first filed.
FOLLOW-UP
BlossomHill Files for $100M Nasdaq IPO in Cancer Drugs
IPO$100M IPO target
BlossomHill Files for $100M Nasdaq IPO in Cancer Drugs
BlossomHill Therapeutics filed for a $100M Nasdaq IPO under ticker BLSM, adding an oncology-focused biotech with $257M in prior funding to a summer pipeline of clinical-stage listings led by J.P. Morgan, Leerink and Guggenheim.